Targeting the TLR pathway with BTK inhibitors in Waldenström's macroglobulinemia

Steven Treon
Professor Steven Treon outlines the impact of the MYD88L265P mutation on the toll-like receptor (TLR) signalling pathway and explains how Bruton's tyrosine kinase (BTK) inhibitors can be used to target the pathway.

Professor Steven Treon outlines the impact of the MYD88LAzD` mutation on the toll-like receptor (TLR) signalling pathway. Prof Treon describes the downstream consequences of the MYD88S8%:Z mutation including that it leads to NFĸB signalling which has implications for growth and survival of malignant B-cells. He also explains pHCK promotes pro-survival signalling in MYD88-mutated B-cells. He explains how Bruton’s tyrosine kinase (BTK) inhibitors can be used to target the pathway in B-cell lymphomas like Waldenström’s macroglobulinemia.

eSJ=HJ%

Qp~u~3 ~CCQf

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión